I-T raids on close aides of two more Congress MLA candidates

Mangaluru, May 15: Dakshina Kannada Superintendent of Police on Friday warned those who are opposing quarantine to either go for it or face legal action under Epidemic Diseases Act.

In a release here on Friday, Mr B M Laxmi Prasad said that schools and hostels have been identified for quarantining those who arrive from other states. Those, who return, will be quarantined in the respective Gram Panchayat/local bodies’ jurisdiction. The public should not panic over the quarantine facility.

The quarantine facility has been introduced in the interest of the general public. If anyone opposes or protests against such facility, then legal action will be initiated against them, he warned.

Udupi, Jan 22: Udupi district authorities was on high alert following the bomb detected at Mangalore International Airport (MIA).

Udupi railway police said that security had been strengthened in all the railway stations, including Padubudri, Senapur, Barkur, Kundapur and Indrali in the district.

The police in mufti and uniform were on constant beats in the railway stations. Besides, dog squads and bomb detection squads have been deputed in the railways stations, they said.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.